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Systemic Sclerosis (SSc) is a rheumatic disease characterized by fibrosis, microvascular
damage and immune dysregulation. Two major subsets, limited cutaneous systemic
sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc) can be defined,
according to the extent of skin involvement. Increasing evidence indicates a role for
galectins in immune and vascular programs, extracellular matrix remodeling and fibrosis,
suggesting their possible involvement in SSc. Here, we determined serum levels of galectin
(Gal)-1 and Gal-3 in 83 SSc patients (dcSSc n  17; lcSSc n  64; ssSSc n  2), and
evaluated their association with clinical manifestations of the disease. Patients with dcSSc
showed lower Gal-3 levels, compared to lcSSc (p  0.003), whereas no considerable
difference in Gal-1 levels was detected between groups. Remarkably, higher
concentrations of Gal-1 were associated with the presence of telangiectasias (p 
0.015), and higher concentrations Gal-3 were associated with telangiectasias (p 
0.021), diarrhea (p  0.039) and constipation (p  0.038). Moreover, lower Gal-3 levels
were associated with the presence of tendinous retractions (p  0.005). Patients receiving
calcium blockers (p  0.048), methotrexate (p  0.046) or any immunosuppressive
treatment (p  0.044) presented lower concentrations of Gal-3 compared to those not
receiving such treatments. The presence of telangiectasia and the type of SSc maintained
their statistical association with Gal-3 (β 0.25; p  0.022 and β 0.26; p  0.017,
respectively) in multiple linear regression models. In conclusion, serum levels of Gal-3
are associated with clinical manifestations of SSc. Among them, the presence of
telangiectasias could be explained by the central role of this lectin in the vascularization
programs.
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INTRODUCTION
Systemic Sclerosis (SSc), also called scleroderma, is an immune-
mediated rheumatic disease, characterized by microvascular damage
and fibrosis. Although skin fibrosis is a typical hallmark in this
progressive disease, patients present different patterns of organ-
based complications. In fact, dysfunction and eventual failure of
almost any internal organ can be observed (Allanore et al., 2015;
Denton and Khanna, 2017). The considerable heterogeneity in the
extent and severity of visceral organ commitment is indeed a major
factor in determining SSc prognosis (Gabrielli et al., 2009). Most
patients with SSc are classified into two major subsets, namely
limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous
systemic sclerosis (dcSSc) subsets (LeRoy et al., 1988), according to
the extent of skin involvement. While in lcSSc skin fibrosis is
restricted to fingers (sclerodactyly), distal extremities and face, the
trunk and proximal extremities are also affected in dcSSc. In
addition, a small number of patients (<5%) present clinical
manifestations (most commonly Raynaud’s phenomenon, digital
ulcers, pulmonary arterial hypertension and scleroderma renal crisis)
and serological features specific to systemic sclerosis, but in the
absence of detectable skin involvement (i.e. systemic sclerosis sine
scleroderma). Moreover, some patients show features of another
connective tissue disease, such as rheumatoid arthritis, polymyositis
or systemic lupus erythematosus, overlapping with systemic
sclerosis. Even though the pathogenesis of SSc is complex and
not completely understood, a distinctive triad of microvascular
damage, dysregulation of innate and adaptive immunity, and
generalized fibrosis in multiple organs characterizes this
heterogeneous disease (LeRoy et al., 1988).
Galectins are a family of endogenous glycan-binding proteins
characterized by a common structural fold and a conserved
carbohydrate recognition domain (CRD) that recognizes glycans
containing the disaccharide N-acetyllactosamine
(Galβ1,4GlcNAc). These soluble proteins can function either in
the extracellular milieu by interacting with amyriad of glycosylated
receptors, or intracellularly by controlling signaling pathways
through protein–glycan or protein–protein interactions (Cerliani
et al., 2017). Several studies substantiate a role for galectin–glycan
interactions in modulating the function of relevant cell surface
receptors, thus modulating signaling pathways that govern
immune and vascular programs, as well as extracellular matrix
remodeling and fibrosis (Cerliani et al., 2017; Elola et al., 2018).
Undoubtedly, the best studied members of the galectin family are
the proto-type Galectin-1 (Gal-1) and the chimera-type galectin-3
(Gal-3) proteins, which are ubiquitously expressed in different
tissues and display a broad range of biological functions. Widely
expressed in inflammatorymicroenvironments, Gal-1 has emerged
as a potent homeostatic signal that shapes immune responses, by
targeting multiple cell types within the innate and adaptive
immune compartments (Sundblad et al., 2017). On the other
hand, Gal-3 exerts mostly pro-inflammatory effects by
reinforcing activation of macrophages, dendritic cells (DCs),
mast cells, and natural killer (NK) cells, as well as T and B
lymphocytes (Sciacchitano et al., 2018), depending on its
intracellular or extracellular localization and the implicated
target cell type. Interestingly, increasing evidence shows that
both Gal-1 and Gal-3 participate in vascular programs leading
to development of blood vessel networks (Croci et al., 2014), and
modulate fibroblast signaling programs, impacting on deposition
of a cross-linked collagen matrix and fibrosis (Elola et al., 2018).
Particularly Gal-3, promotes fibroblast proliferation and
transformation, and mediates collagen production, modulating
fibrogenesis in diverse organs, including liver, kidney, lung and
myocardium (Li et al., 2014).
Given the involvement of Gal-1 and Gal-3 in angiogenesis,
immunity and extracellular matrix remodeling, a role of these
lectins in SSc development, characterized by vascular alterations,
inflammation and fibrosis has been proposed. In this line, previous
studies evaluated possible differences in Gal-1 (Yanaba et al., 2016)
and Gal-3 (Taniguchi et al., 2012; Koca et al., 2014; Gruszewska
et al., 2020) serum levels between SSc patients and controls, and
reported different paradoxical results. In addition, possible
associations between Gal-3 serum levels and SSc variants
(Taniguchi et al., 2012; Stochmal et al., 2020), or between this
lectin and specific clinical manifestations and laboratory markers
of the disease has also been documented (Taniguchi et al., 2012;
Koca et al., 2014; Yanaba et al., 2016; Faludi et al., 2017; Hromádka
et al., 2017; Gruszewska et al., 2020; Stochmal et al., 2020), although
with highly dissimilar results. Thus, further studies are required to
reconcile these paradoxical different findings and to define a
possible association between galectins and SSc progression.
Due to the remarkable heterogeneity in clinical disease
signatures and to our limited understanding of the complex
mechanisms underlying SSc development, the diagnosis and
clinical management of patients with SSc is extremely
challenging. Despite revised classification criteria, no scheme is
completely useful to adequately capture the whole complexity and
heterogeneity of this disease. Moreover, personalized assessment of
disease manifestations, stratification of risk of future complications
and individualized treatment of SS impose major challenges. New
validated, non-invasive biomarkers are required to aid in the
diagnosis, assessment of disease activity and response to
therapeutic approaches in SSc (Wermuth et al., 2018). In line
with this demand, and considering the previous inconclusive
findings, we aimed at determining serum levels of Gal-1 and
Gal-3 in patients with SSc and to evaluate possible associations
with clinical manifestations of the disease and treatment options.
MATERIALS AND METHODS
Patients
A descriptive, observational and cross-sectional study was
conducted. Data were obtained retrospectively from the
analysis of the electronic database of patients with SSc from
the Rheumatology Service at the Hospital de Clínicas “José de San
Martín”, University of Buenos Aires. Patients with a diagnosis of
SSc, over 18 years of age, who met the ACR/EULAR 2013 criteria
for SSc, with at least one visit to the Rheumatology Service
between January 2008 and June 2018 and who had a serum
sample in our library were included. Patients whose available data
were not sufficient to meet the classification criteria, did not fulfill
the definition of clinical variants of SSc, or did not have record of
Frontiers in Pharmacology | www.frontiersin.org April 2021 | Volume 12 | Article 6506052
Sundblad et al. Galectins in Systemic Sclerosis Patients
the date of diagnosis, clinical manifestations or determination of
specific autoantibodies, were excluded. Patients were informed in
detail about the study, and written consent was obtained in
accordance with the Declaration of Helsinki. The protocol was
approved by Ethics and Research Committees of Hospital de
Clínicas “José de San Martín” and Instituto de Biología y
Medicina Experimental (IBYME).
Clinical Features
Gender, age and time of evolution of SSc (from diagnosis to
galectin determination) were recorded. Clinical forms of the
disease (dcSSc, lcSSc or sineSSc) were recorded according to
LeRoy classification (LeRoy et al., 1988). The presence (current
or past) of skin involvement (edematous phase or skin fibrosis),
calcinosis, telangiectasias, arthritis (identified by rheumatologist),
muscle weakness, Raynaud’s phenomenon, interstitial lung
disease (ILD) [defined by Computed Tomography resolution
of the chest according to the definitions of the American
Thoracic Society/European Respiratory Society 2002
consensus], pulmonary hypertension (PHT) (defined as PSAP
≥36 mmHg by echocardiogram and/or ≥25 mmHg by right
catheterization), ischemic lesions in fingers (pitting scars,
digital ulcers, ES amputations) and dysphagia was also
recorded. Specific autoantibodies (anti topoisomerase I, Scl 70;
anti centromere; ACA) were determined, and overlapping with
other connective tissue diseases was recorded according to expert
diagnosis and to classification criteria at the date of this study.
Treatment at the time of inclusion in the study was recorded,
as follows: calcium blockers (CCBs), phosphodiesterase 5
inhibitors (IPED5), endothelin antagonists, pentoxifylline,
cilostazol, prostaglandin analogs, proton pump inhibitors,
prokinetics (domperidone, cisapride/mosapride),
glucocorticoids, methotrexate (MTX), mycophenolate mofetil,
azathioprine, cyclophosphamide, D-penicillamine, human
immunoglobulin, and biologic DMARs (TNF inhibitors,
abatacept, tocilizumab, and rituximab).
Galectin-1 and Galectin-3 Determinations
Serum samples were aliquoted to minimize damage due to
freezing and thawing, and stored frozen at –20°C at the
Rheumatology Service, Hospital de Clínicas “José de San
Martín”. Serum Gal-1 was determined using an in-house
ELISA as described (Croci et al., 2012). Serum Gal-3 level was
determined using a human Gal-3 ELISA kit (R&D Systems;
DY1154), following manufacturer´s instructions.
Statistical Analysis
Categorical variables, expressed as frequency and percentage,
were analyzed with the chi-square test or Fischer’s exact test,
as appropriate. Continuous variables were expressed as median
and interquartile range or mean and standard deviation,
according to their distribution, and were analyzed with
Student’s t test, ANOVA or Mann Whitney or Kruskal Wallis
U test, as appropriate. Correlation tests were performed
by Spearman’s test and multiple linear regressions. A value of
p < 0.05 was considered significant.
RESULTS
From a total of 83 patients, 95% (79/83) were women, with a
median (m) age of 58 years (IQR 47–66 years), a median time of
evolution of SSc of 5 years (IQR 1–10 years) and a follow-up time
of 22 months (IQR 0–63 months). Regarding the clinical variants,
TABLE 1 | Clinical Manifestations and Autoantibodies Levels in SSc Patients
Clinical Manifestations Total lcSSc dcSSc ssSSc
n = 83 n = 64 n = 17 n = 2
Raynaud 82 (99) 64 (100) 17 (100) 1 (50)
Skin Fibrosis 72 (87) 55 (86) 17 (100) 0 (0)
Puffy fingers/hands 37 (45) 31 (48) 6 (35) 0 (0)
Microstomy 19 (23) 12 (19) 7 (43) 0 (0)
Tendinous retractions 48 (58) 23 (36) 15 (93) 0 (0)
Telangiectasia 62 (75) 49 (76) 12 (70) 1 (50)
Calcinosis 20 (24) 15 (23) 5 (29) 0 (0)
Pitting scars 30 (36) 18 (28) 12 (70) 0 (0)
Digital ulcers 22 (26) 14 (22) 8 (47) 0 (0)
Digital amputation 6 (7) 4 (6) 2 (12) 0 (0)
Disphagia 31 (37) 23 (36) 7 (41) 1 (50)
Diarrhea 15 (18) 13 (20) 2 (12) 0 (0)
Constipation 22 (26) 19 (29) 3 (18) 0 (0)
ILD 28 (34) 18 (28) 9 (53) 1 (50)
PHT 18 (22) 13 (20) 3 (18) 2 (100)
Arthritis 11 (13) 7 (11) 3 (18) 1 (50)
Muscular weakness 5 (6) 3 (5) 1 (6) 1 (50)
Gastroesophageal reflux 36 (43) 26 (40) 9 (53) 1 (50)
Autoantibodies
ANA 82 (99) 63 (98) 17 (100) 2 (100)
ACA 44 (53) 42 (66) 2 (12) 0 (0)
Scl-70 20 (24) 8 (12) 11 (65) 1 (50)
Data are expressed as n (%). ILD, Intersticial Lung Disease; PHT, Pulmonary
Hypertension. ANA, Antinuclear antibodies; ACA, anticentromere antibodies; Scl 70, anti
topoisomerase 1.
FIGURE 1 | Galectin concentrations in sera from patients with systemic
sclerosis (SSc). Upper panel, Gal-1; lower panel, Gal-3. lcSSc, limited
cutaneous SSc (n  64); dcSSc, diffuse cutaneous SSc (n  17). Mann-
WhitneyU test was used to compare galectin levels between dcSSc and
lcSSc patients. **p < 0.01.
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77% of patients (64/83) presented lcSSc, 21% (17/83) dcSSc and
2% (2/83) sineSSc. In addition, 23% (19/83) of patients were
classified as overlap syndrome, because of the clinical overlap
with other autoimmune diseases (one or more entities): 10
Sjögren’s syndrome, 6 Systemic lupus erythematosus, 4
Antiphospholipid syndrome, 2 Primary biliary cholangitis and
5 others (2 autoimmune inflammatory myopathy, 1 ANCA-
associated vasculitis, 1 Rheumatoid arthritis, 1 Celiac disease).
Clinical features and frequency of autoantibodies are listed in
Table 1.
When analyzing the whole population serum samples, Gal-1
concentration was m 162.27 ng/ml (IQR 114.65–235.20 ng/ml)
and Gal-3 concentration was m 2.02 ng/ml (IQR 1.31–2.97 ng/ml).
When considering gender, women presented higher concentration
TABLE 2 | Clinical features and galectin concentrations in SSc patients (n  83)
Clinical signs
and symptoms
Presence/ absence N Gal-1 ng/ml p* Gal-3 ng/ml p*
Skin fibrosis (+) 72 218.48 0.64 2.20 0.29
(–) 11 189.91 2.65
Puffy fingers/hands (+) 37 196.99 0.44 2.36 0.52
(–) 46 228.93 2.17
Microstomy (+) 19 308.00 0.08 2.02 0.34
(–) 64 185.07 2.33
Tendinous retractions (+) 48 208.69 0.77 1.84 0.005
(–) 35 220.53 2.63
Telangiectasias (+) 62 234.00 0.015 2.45 0.021
(–) 21 157.68 1.69
Calcinosis (+) 20 180.35 0.35 2.14 0.63
(–) 63 225.59 2.29
Pitting scars (+) 30 217.87 0.90 1.92 0.07
(–) 53 212.89 2.45
Digital ulcers (+) 22 199.99 0.67 2.10 0.50
(–) 61 219.99 2.31
Digital Amputation (+) 6 253.14 0.60 1.57 0.18
(–) 77 211.70 2.31
Dysphagia (+) 31 218.84 0.87 2.36 0.58
(–) 52 212.22 2.20
Gastroesophageal reflux (+) 36 189.05 0.26 2.27 0.93
(–) 47 235.31 2.25
Diarrhea (+) 15 199.00 0.72 2.89 0.039
(–) 68 218.15 2.12
Constipation (+) 22 220.59 0.86 2.75 0.038
(–) 61 212.56 2.08
ILD (+) 28 277.15 0.08 2.16 0.63
(–) 55 182.90 2.31
PHT (+) 18 224.28 0.80 2.16 0.71
(–) 65 212.04 2.28
Arthritis (+) 11 163.02 0.33 2.37 0.75
(–) 72 222.59 2.24
Muscular weakness (+) 5 157.34 0.48 1.32 0.09
(–) 78 218.37 2.32
*p-value obtained from comparing Gal-1 or Gal-3 levels from patients presenting or not each clinical manifestation (Mann-Whitney U test). ILD, Interstitial lung disease; PHT, Pulmonary
hypertension.
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of Gal-1 (m 166 ng/ml [IQR 117.93–237.93 ng/ml]) than men
(m 104.96 ng/ml [IQR 23.87–129.89 ng/ml]) (p  0.019).
However, there was no considerable difference in Gal-3
concentrations between men and women (m 2.02 ng/ml [ICR
1.32–2.97 ng/ml] vs. 1.36 ng/ml [ICR 0.26–4.46 ng/ml]) (p  0.09).
When stratifying by clinical type of SSc (Figure 1), patients with lcSSc
presented amedian of 160 ng/ml (IQR 112.85–213.51 ng/ml) for Gal-
1, and patients with dcSSc showed a median of 188.78 ng/ml (IQR
129.74–317.25 ng/ml) (p  0.13). Regarding Gal-3, concentrations
were 2.32 ng/ml (IQR 1.37–3.08 ng/ml) and 1.50 ng/ml (IQR
0.51–1.95 ng/ml) in patients with lcSSc and dcSSc respectively (p 
0.003). Patients with overlap syndrome had a median Gal-1 of
142.84 ng/ml (IQR 114.65–206.96 ng/ml) and Gal-3 of 2.00 ng/ml
(IQR 1.38–2.89 ng/ml). Differences in Gal-1 and Gal-3 levels between
patients with and without overlap were not significant (p  0.41 and
p  0.84, respectively). We found no correlation between the time of
evolutionmeasured in years and the concentrations of Gal-1 and Gal-
3 (rho 0.05 and 0.02 respectively).
To further investigate the association of serum Gal-1 and Gal-
3 with clinical manifestations of SSc, patients were classified into
2 groups according to the presence or absence of organ
involvement, and galectin concentrations were assessed in
these two groups (Table 2). We found a statistically significant
association between higher values of Gal-1 and the presence of
telangiectasias (234 ng/ml vs. 157.68 ng/ml, p  0.015) and
between higher Gal-3 values and the presence of
telangiectasias (2.45 ng/ml vs. 1.69 ng/ml, p  0.021),
diarrhea (2.89 ng/ml vs. 2.12 ng/ml, p  0.039) and
constipation (2.75 ng/ml vs. 2.08 ng/ml, p  0.038)
(Table 2). On the contrary, we found a statistically
significant association between lower Gal-3 levels and the
presence of tendinous retractions (1.84 ng/ml vs. 2.63 ng/ml,
p  0.005). Since higher concentrations of Gal-3 were found in
patients with lcSSc, and gastrointestinal manifestations and
telangiectasias were more frequent in this clinical form of SSc
(Table 1), the association of these clinical manifestations with
the lcSSc clinical variant was evaluated. Data revealed no
statistically significant association between these clinical
parameters. Likewise, given the lower concentration of Gal-3 in
patients with dcSSc, we evaluated the association of tendon
retractions with this clinical form of the disease. We found a
statistically significant association between Gal-3 and tendon
retractions in dcSCC patients (p  0.005).
We then evaluated the association of galectins concentrations
and the presence of SSc-specific autoantibodies. ACA was present
in 53% of patients and Scl-70 in 24%. No association was found
between Gal-1 and ACA levels (201.40 ng/ml vs. 229.69 ng/ml, p 
0.49) or between Gal-1 and Scl-70 (235.03 ng/ml vs. 208, 23 ng/ml,
p  0.058). Similarly, we did not find association between Gal-3 and
ACA (2.50 ng/ml vs. 1.98 ng/ml, p  0.07), nor between Gal-3 and
Scl-70 (2.03 ng/ml vs. 2.33 ng/ml, p  0.36).
We then analyzed possible relationships between Gal-1 and/or
Gal-3 serum concentrations and patient treatment at time of
determinations. We found lower concentrations of Gal-3 in
patients receiving calcium blockers (2.05 ng/ml vs. 2.64 ng/ml, p 
0.048) and in patients receiving MTX (1.54 ng/ml vs. 2.37 ng/ml, p 
0.046) compared to those not receiving such treatments (Table 3). In
addition, when considering all immunosuppressive treatments (IT)
together and grouped patients according to this variable, we found
significantly lower concentrations of Gal-1 in dcSSc patients receiving
IT (171.32 ng/ml vs. 332.84 ng/ml, p  0.02), and decreased levels of
Gal-3 in total SSc patients receiving IT (1.74 ng/ml vs. 2.46 ng/ml, p 
0.044) compared to patients not receiving this treatment (Table 4).
Although there has been no compensation for multiple testing,
in multiple linear regression models the presence of telangiectasia
and the type of SSc maintained their statistical association with
TABLE 3 | Pharmacological treatments in SSc patients studied
Drug CCB PDE5-I ERAs Cilostazol Pentoxifylline PGA PPIs Prokinetics
Total SSc 54 (65) 24 (29) 2 (2.4) 12 (14.5) 9 (10.8) 0 (0) 58 (69.9) 5 (6)
dcSSc 14 (82) 7 (41) 1 (6) 2 (12) 3 (18) 0 (0) 11 (65) 0 (0)
lcSSc 40 (62) 16 (25) 0 (0) 10 (16) 6 (9) 0 (0) 45 (70) 5 (8)
Drug GC MTX MFM/MFS CYC Azathiopine D-Pen Ig IV bDMARs
Total SSc 11 (13) 11 (13) 3 (3.6) 1 (1.2) 5 (6) 4 (4.8) 0 (0) 0 (0)
dcSSc 4 (23) 6 (35) 2 (12) 1 (6) 1 (6) 1 (6) 0 (0) 0 (0)
lcSSc 6 (9) 5 (8) 1 (2) 0 (0) 3 (5) 3 (5) 0 (0) 0 (0)
Data are expressed as n (%). The numbers of dcSSC + lcSSC may differ from total SSc as patients with ssSSc (n2) are not shown. CCB, calcium channel blockers; PDE5-I,
phosphodiesterase 5 inhibitors; ERAs, endothelin receptor antagonists; PGA, prostaglandin analogs; PPIs, proton pump inhibitors; GC, glucocorticoids; MTX, methotrexate; MFM,
mycophenolate mofetil/MFS, mycophenolate sodium; CYC, cyclophosphamide; D-Pen, D-penicillamine; IV Ig, intravenous immunoglobulins; bDMARS, biological disease-modifying
antirheumatic drugs. IT, immunosuppresive treatment.
TABLE 4 | Galectin concentrations in SSc patients with our without
immunosuppresive treatment (IT).
Patients All (n = 83) dcSSc (n = 17) lcSSc (n = 64)
Receiving IT 23 (27.7) 10 (58.8) 12 (18.7)
Mean Gal-1 on IT 183.83 ± 139.32 171.32 ± 73.29 193.42 ± 180.27
Mean Gal-1 off IT 228.21 ± 202.16 332.84 ± 143.88 214.39 ± 204.74
p  0.35 p  0.02 p  0.67
Mean Gal-3 on IT 1.74±0.90 1.47 ± 0.77 2.00 ± 0.95
Mean Gal-3 off IT 2.46 ± 1.38 1.55 ± 1.49 2.59 ± 1.31
p  0.045 p  0.81 p  0.22
Data are expressed as n (%). The numbers of dcSSC + lcSSC may differ from total SSc as
patients with ssSSc (n  2) are not shown. CCB, calcium channel blockers; PDE5-I,
phosphodiesterase 5 inhibitors; ERAs, endothelin receptor antagonists; PGA, prostaglandin
analogs; PPIs, proton pump inhibitors; GC, glucocorticoids; MTX, methotrexate; MFM,
mycophenolate mofetil/MFS, mycophenolate sodium; CYC, cyclophosphamide; D-Pen,
D-penicillamine; IV Ig, intravenous immunoglobulins; bDMARS, biological disease-
modifying antirheumatic drugs. IT, immunosuppresive treatment.
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Gal-3 concentrations (β 0.25; p  0.022 and β 0.26; p  0.017,
respectively). However, the association between clinical
manifestations of disease and Gal-1 concentrations did not
reach statistical significance.
DISCUSSION
Systemic sclerosis, though an uncommon disease, has a high
morbidity and mortality rates. Despite significant efforts in
developing new classification criteria to improve earlier
diagnosis, none of the proposed systems reflect adequately the
heterogeneity of clinical manifestations of SSc (Denton and
Khanna, 2017). Thus, an improved understanding of the
pathological mechanisms underlying SSc will enable a better
management of the disease, including improved classification
and more systematic assessment and follow-up.
Compelling evidence suggesting the involvement of galectins
in the control of immune and vascular programs, as well as in
fibrotic processes support a role for these proteins in SSc.
Nevertheless, our current understanding on the impact of
galectins in SSc and their clinical relevance remains elusive.
Here, we demonstrated the presence of lower concentrations
of circulating Gal-3 in patients with diffuse compared to
localized forms of SSc, whereas no differences in Gal-1 levels
were observed between both groups. Also, associations with
clinical manifestations and treatment at time of serological
determinations were observed.
Regarding a possible association between circulating Gal-1
and the type of SSc, we found no significant differences between
patients with diffuse and limited cutaneous forms, in agreement
with previous findings (Yanaba et al., 2016). Nevertheless,
considering that dcSSc patients receiving IT showed significant
lower Gal-1 levels, the possibility that any potential statistically
significant difference in circulating Gal-1 between lcSSc and
dcSSC might be blurred out by high prevalence of IT
treatment among dcSSc patients cannot be ruled out.
Moreover, with regards to associations with clinical
manifestations, we found significantly higher levels of Gal-1 in
patients with associated telangiectasias, a phenomenon associated
with endothelial dysfunction, although no association was
observed with the presence of digital ulcers (DU) and pitting
scars, in contrast to previous reports (Yanaba et al., 2016), calling
into question the suggested protective role for Gal-1 in the
development of digital vasculopathy in SSc (Yanaba et al.,
2016). Finally, no association was detected between Gal-1
serum levels and the presence of specific SSc antibodies.
Regarding Gal-3, we found significantly higher levels of this
lectin in patients with lcSSc as compared with those transiting the
diffuse variant, in line with previous findings that showed serum
Gal-3 levels relatively decreased in patients with dcSSc compared
with lcSSc (Taniguchi et al., 2012). Strikingly, the opposite
outcome was recently reported (Stochmal et al., 2020),
whereas no significant differences were reported in a smaller
cohort (Koca et al., 2014). As discussed below, disparity in the
treatment schemes frequently used in the different cohorts
analyzed may explain these discrepancies.
Several reports addressed a possible association between Gal-3
serum levels and clinical manifestations of SSc. In accordance
with our findings, no significant differences in Gal-3 were found
between patients presenting or not DU or pulmonary vascular
involvement (Koca et al., 2014), while higher levels were reported
only in SSc patients presenting both clinical signs (Taniguchi
et al., 2012). Interestingly, we found no association between
serum Gal-3 levels and the presence of cutaneous sclerosis.
Despite a relative decrease compared to lcSSc, serum Gal-3
levels were found to correlate with the extent of skin fibrosis
in dcSSc (Taniguchi et al., 2012). In lesional skin of SSc patients,
however, increased local Gal-3 expression was associated with a
higher modified Rodnan’s skin score (Mora and Zubieta, 2020),
suggesting that heightened local, but not systemic, Gal-3 might be
responsible of cutaneous fibrosis. Notably, we found a significant
association between lower Gal-3 values and the presence of
tendinous retractions. Given that this lectin is highly
associated with fibrotic processes, higher levels of Gal-3 were
expected in these patients. Nevertheless, the significant
associations between tendon retractions and the dcSSc variant
described herein, and between lower Gal-3 levels and this clinical
form, may provide a possible explanation for this finding.
To our knowledge, no previous study reported an association
between higher Gal-3 levels and the presence of telangiectasias.
Microvascular alterations, characterized by endothelial cell damage,
together with mononuclear cell infiltrates and slowly developing
fibrosis, are important features of tissue lesions in SSc.
Notwithstanding the resulting adaptive response to hypoxia, a
paradoxical increase of both pro-angiogenic and angiostatic
factors have been detected in early SSc, leading to defective
vascularization (Gabrielli et al., 2009). Accordingly, galectins have
been shown to influence endothelial cell compartments affecting
vascular remodeling and angiogenesis. This effect could explain, at
least in part, the association found between higher concentrations of
Gal-1 and Gal-3 and the presence of telangiectasias, regardless of the
type of SS. In particular, Gal-1 stimulates the migration and
proliferation of endothelial cells (Thijssen et al., 2010; Croci et al.,
2012; Bastón et al., 2014; van Beijnum et al., 2016), and
glycosylation-dependent binding of this lectin to VEGFR2
preserves angiogenesis even in the absence of VEGF (Croci et al.,
2014), while both VEGF-dependent and independent proangiogenic
effects have been described for Gal-3 (Funasaka et al., 2014).
We found a lower concentration of Gal-3 in patients receiving
MTX compared to those not receiving such treatment. Given that
most patients taking this drug belong to the dcSSc group, leading
to a statistically significant association between dcSSc and the use
of MTX (p  0.008), this finding could eventually explain the
reduction in Gal-3 found in dcSSC patients. Moreover, in contrast
to reports in patients receiving or not GC, and treated or not with
at least one disease-modifying anti-rheumatic drug (DMARD)
(Koca et al., 2014), we found a significant association between
lower Gal-3 levels and the use of any immunossuppresive
treatment. Differences in the DMARD most often used, in the
frequency of GC usage, as well as in the cohort size and
composition, may explain this discrepancy. Similarly to clinical
studies in other rheumatologic diseases (Mendez Huergo et al.,
2019), and in view of previous findings demonstrating cell type-
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and drug-specific control mechanisms of Gal-3 expression
(Maldonado et al., 2011; Sundblad et al., 2011; Dabelic et al.,
2012), differences in treatment schemes should be considered
when comparing reports from distinct cohorts. We also found a
lower concentration of Gal-3 in patients receiving calcium
blockers; though the association between dcSSc and the use of
CCB was not statistically significant, we found a biological trend
in these patients (83% in dcSSc vs. 62% in lcSSc) that may
eventually help to explain this result.
Notably, women presented significantly higher levels of Gal-1 than
men, and in contrast to the reported for general population (Cediel
et al., 2021), no differences were found in Gal-3 levels. Though
variations in fat mass and hormonal conditions might explain
these differences, further studieswill help to understand thesefindings.
In conclusion, despite discrepancies due to the heterogeneity
of the studied groups, our results and those involving other
patient cohorts suggest that Gal-3 may be associated with
clinical manifestations and pathological events relevant to
development of SSc. Among them, the presence of
telangiectasias, which showed clear statistical significance with
Gal-3 levels, deserves special attention as it might reflect the
central role of this lectin in vascular remodeling and angiogenesis.
Further prospective studies, with standardized inclusion criteria
will be necessary to define whether Gal-3 is a prominent
biomarker of disease activity and/or severity in SSc.
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